Raritan: Johnson & Johnson has received priority review from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) filed for TAR-200, an intravesical gemcitabine ...

Johnson & JohnsonJNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

M raised its full-year profit forecast and projected a smaller tariff-related hit to its 2025 earnings on Friday, weeks after ...

Naturally, dividend stocks, especially high-yielding ones, are alluring. That said, nothing in life is guaranteed, and ...

The Kiplinger Dividend 15 are poised to benefit as falling interest rates lure investors back to dividend-paying stocks.